Goran Walldius

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
  2. ncbi [Apolipoproteins are better risk markers than conventional lipids]
    Goran Walldius
    Konung Gustaf V s forskningsinstitut, Solna, AstraZeneca AB, Sodertalje
    Lakartidningen 104:2612-3. 2007
  3. ncbi Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden AstraZeneca, Sodertalje, Sweden
    Nutr Metab Cardiovasc Dis 17:565-71. 2007
  4. ncbi Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Curr Opin Cardiol 22:359-67. 2007
  5. ncbi [The apoB/apoA-I ratio is better myocardial infarction marker than lipids]
    Goran Walldius
    Karolinska Institutet, Stockholm
    Lakartidningen 103:751-2. 2006
  6. ncbi Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:259-66. 2006
  7. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
  8. ncbi [Apolipoproteins are new and better risk indicators of myocardial infarction]
    Göran Walldius
    Konung Gustaf V forskningsinstitut, Karolinska Institutet, Stockholm
    Lakartidningen 101:1188-94. 2004
  9. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
  10. ncbi The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004

Detail Information

Publications19

  1. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
    ..Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA-I ratio...
  2. ncbi [Apolipoproteins are better risk markers than conventional lipids]
    Goran Walldius
    Konung Gustaf V s forskningsinstitut, Solna, AstraZeneca AB, Sodertalje
    Lakartidningen 104:2612-3. 2007
  3. ncbi Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden AstraZeneca, Sodertalje, Sweden
    Nutr Metab Cardiovasc Dis 17:565-71. 2007
    ....
  4. ncbi Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Curr Opin Cardiol 22:359-67. 2007
    ..To compare the potential of high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo) A-I, the major protein in HDL particles, in predicting cardiovascular risk. Pros and cons for using these risk markers are discussed...
  5. ncbi [The apoB/apoA-I ratio is better myocardial infarction marker than lipids]
    Goran Walldius
    Karolinska Institutet, Stockholm
    Lakartidningen 103:751-2. 2006
  6. ncbi Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:259-66. 2006
    ....
  7. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
    ..We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol...
  8. ncbi [Apolipoproteins are new and better risk indicators of myocardial infarction]
    Göran Walldius
    Konung Gustaf V forskningsinstitut, Karolinska Institutet, Stockholm
    Lakartidningen 101:1188-94. 2004
    ..Methodological advantages speak in favour of measuring apoB and apoA-I in clinical practice...
  9. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
    ..Measurement of these apolipoproteins could improve cardiovascular risk prediction...
  10. ncbi The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004
    ..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
  11. ncbi Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population
    Martin J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Med 44:607-15. 2012
    ..We aimed to assess the impact of CKD on the risk of fatal or non-fatal ischemic and hemorrhagic stroke in both men and women...
  12. ncbi Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
    Ingmar Jungner
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden
    Am J Cardiol 97:943-6. 2006
    ..The strongest single lipoprotein-related risk factor was the apo-B/apo-A-I ratio. In conclusion, these results provide further confirmation of the importance of determining apo-B and apo-A-I in routine clinical practice...
  13. pmc Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population
    Justo Sierra-Johnson
    Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, Building L8 03, S 17176 Stockholm, Sweden
    Eur Heart J 30:710-7. 2009
    ....
  14. ncbi Country of birth-specific and gender differences in prevalence of diabetes in Sweden
    Axel C Carlsson
    Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, Sweden
    Diabetes Res Clin Pract 100:404-8. 2013
    ..The aim was to investigate country or region of birth-specific prevalence and gender differences of diabetes in residents in Sweden, using Swedish-born men and women as referent...
  15. ncbi Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease
    Martin J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Med 44:262-70. 2012
    ..To evaluate dyslipidemia as predictor of myocardial infarction (MI) in subjects with or without chronic kidney disease (CKD)...
  16. ncbi Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials
    I Jungner
    CALAB Research and CALAB Medical Laboratories, S t Göran Hospital, Stockholm, Sweden
    Clin Chem 44:1641-9. 1998
    ....
  17. ncbi Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort
    Håkan Malmström
    Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 9:e111463. 2014
    ..Fructosamine is a glycemic biomarker which may be useful for indication and control of diabetes respectively...
  18. ncbi Renal function assessed by two different formulas and incidence of myocardial infarction and death in middle-aged men and women
    M J Holzmann
    Department of Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden
    J Intern Med 267:357-69. 2010
    ..We evaluated glomerular filtration rates (GFR) estimated by the Modification of Diet in Renal Disease study (GFR-MDRD) equation and the Mayo formula (GFR-Mayo) as predictors of myocardial infarction and death...
  19. ncbi The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis
    J Regnstrom
    King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden
    Atherosclerosis 125:217-29. 1996
    ..The relevance of these observations for the proposed role of lipid oxidation in atherosclerosis is discussed...